Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acasti Pharma Inc. ACST
$0.47
-$0.01 (-1.82%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
20972477.00000000
-
week52high
1.05
-
week52low
0.34
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.52006900
-
EPS
-0.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
19 июн 2023 г. в 12:30
Описание компании
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Perform | Outperform | 25 ноя 2020 г. |
| B. Riley FBR | Buy | Neutral | 25 ноя 2020 г. |
| Aegis Capital | Hold | Buy | 25 ноя 2020 г. |
| Aegis Capital | Hold | Buy | 02 сент 2020 г. |
| Oppenheimer | Perform | Outperform | 01 сент 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Olds Donald | A | 45000 | 45000 | 28 сент 2022 г. |
| Kavuru Vimal | A | 45000 | 45000 | 28 сент 2022 г. |
| Derby Michael | A | 85000 | 85000 | 28 сент 2022 г. |
| Canan John | A | 45000 | 45000 | 28 сент 2022 г. |
| D'Alvise Janelle | A | 560000 | 560000 | 22 июн 2022 г. |
| Ford Brian D. | A | 165000 | 165000 | 22 июн 2022 г. |
| Kottayil George | A | 50000 | 50000 | 22 июн 2022 г. |
| Lemieux Pierre | A | 165000 | 165000 | 22 июн 2022 г. |
| Olds Donald | A | 42100 | 42100 | 12 ноя 2021 г. |
| Canan John | A | 42100 | 42100 | 12 ноя 2021 г. |
Новостная лента
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
28 февр 2023 г. в 11:18
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript
Seeking Alpha
14 февр 2023 г. в 15:53
Acasti Pharma Inc. (NASDAQ:ACST ) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET Company Representatives Jan D'Alvise - President, Chief Executive Officer Brian Ford - Chief Financial Officer Pierre Lemieux - Chief Operating and Scientific Officer, Co-Founder Prashant Kohli - Chief Commercial Officer Robert Blum - Lytham Partners Conference Call Participants Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright Operator Good day, and welcome to the Acasti Pharma Reports Third Quarter of Fiscal Year 2023 Financial Results and Business Update Call.
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
GlobeNewsWire
24 янв 2023 г. в 16:15
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
GlobeNewsWire
13 янв 2023 г. в 09:00
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
GlobeNewsWire
05 янв 2023 г. в 09:00
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures.